Canaccord analyst George Gianarikas raised the firm’s price target on ASP Isotopes (ASPI) to $8.50 from $4.50 and keeps a Buy rating on the shares. The firm believes the company holds significant promise with enrichment technology that could dramatically reduce the cost of isotopes for use in nuclear energy, nuclear medicine, and semiconductors; and strong margin and free cash flow potential.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASPI:
- Alphabet, AMD report Q3 earnings beats: Morning Buzz
- ASP Isotopes enters into term sheet with TerraPower
- ASP Isotopes announces enrichment of Ytterbium-176 using Quantum Enrichment
- ASP Isotopes initiated with a Buy at Canaccord
- ASP Isotopes completes construction phase of Ytterbium-176 enrichment facility